Patent expiry and biosimilars: difference between revisions
Diff·revision 28 → 29·16:46, 16 Jun 2026
Difference between revision 28 and revision 29 of Patent expiry and biosimilars. This revision changed no lines of source — the edit was a null or whitespace change.
| Revision 28 — 11:12, 22 May 2026 AnalyticalAnnie (talk) consistent en dashes in ranges 4,553 bytes ±0 | Revision 29 — 16:46, 16 Jun 2026 ShortageShona (talk) state that research-use-only labelling is a commercial category, not an approval 4,553 bytes ±0 | ||
|---|---|---|---|
| — | No change to the page source. | — |